Prophylatic use of IV nalmefene to prevent epidural opioid-induced pruritus: A multicenter, randomized clinical trial

J Clin Anesth. 2024 Feb:92:111301. doi: 10.1016/j.jclinane.2023.111301. Epub 2023 Oct 19.

Abstract

Study objective: The incidence of pruritus from neuraxial opioids is about 60%. Pruritus causes discomfort and decreases the quality of recovery. This randomized double-blinded clinical trial was aimed to evaluate the prophylactic effects of a single dose IV nalmefene on the incidence and severity of epidural opioid-induced pruritus within 24 h after surgeries.

Design: A two-center, randomized, double blinded, controlled clinical trial.

Setting: The study was conducted from March 2022 to February 2023 at two tertiary care hospitals in China.

Patients: Patients aged between 18 and 80 years-old who underwent elective surgeries and received epidural analgesia intra- and post-operatively were screened for study enrollment. A total of 306 patients were enrolled, 302 patients underwent randomization and 296 patients were included in the final analysis.

Interventions: The nalmefene group was prophylactically given 0.5 μg/kg nalmefene intravenously while the control group was given the same volume of saline.

Measurements: The primary endpoint was the incidence of pruritus within 24 h after surgeries. The secondary endpoints included time of the first patient-reported pruritus, severity of pruritus after surgeries, severity of acute pain scores after surgeries and other anesthesia/analgesia related side effects.

Main results: Pruritus occurred in 51 of the 147 (34.69%) patients in the control group and 35 of the 149 (23.49%) patients in the nalmefene group (odds ratio, 0.58; 95% CI, 0.35 to 0.96; P = 0.034) within 24 h postoperatively. Nalmefene group demonstrated delayed onset of pruritus, reduced severity of pruritus and decreased vomiting within 24 h after surgery. There were no significant differences in postoperative analgesia and the incidence of other anesthesia/analgesia associated side effects.

Conclusions: A single dose of 0.5 μg/kg nalmefene intravenously significantly reduced the incidence and severity of epidural-opioid induced pruritus within 24 h after surgery without affecting the efficacy of epidural analgesia.

Trial registration: Chinese Clinical Trial Registry (www.chictr.org.cn) and the registration number is ChiCTR2100050463. Registered on August 27th, 2021.

Keywords: Epidural opioid; Nalmefene; Pruritus.

Publication types

  • Randomized Controlled Trial
  • Multicenter Study
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Adolescent
  • Adult
  • Aged
  • Aged, 80 and over
  • Analgesia, Epidural* / adverse effects
  • Analgesics, Opioid*
  • Double-Blind Method
  • Humans
  • Middle Aged
  • Morphine
  • Pain, Postoperative / drug therapy
  • Pain, Postoperative / prevention & control
  • Pruritus / chemically induced
  • Pruritus / epidemiology
  • Pruritus / prevention & control
  • Young Adult

Substances

  • Analgesics, Opioid
  • nalmefene
  • Morphine

Associated data

  • ClinicalTrials.gov/ChiCTR2100050463